Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.

Hsu, Fei-Ting

Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling. [electronic resource] - International journal of oncology Jul 2014 - 177-88 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1791-2423

10.3892/ijo.2014.2423 doi


Animals
Antineoplastic Agents--administration & dosage
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Hepatocellular--pathology
Cell Line, Tumor
Drug Synergism
Humans
Hydroxamic Acids--administration & dosage
Liver Neoplasms--pathology
Liver Neoplasms, Experimental
MAP Kinase Signaling System--drug effects
Male
Mice
Mice, Nude
Niacinamide--administration & dosage
Phenylurea Compounds--administration & dosage
Protein Serine-Threonine Kinases--metabolism
Sorafenib
Vorinostat
Xenograft Model Antitumor Assays
NF-kappaB-Inducing Kinase